MOTS-c · Research brief

Retatrutide GLP-3 Research Peptide: What Trials Show

Real Peptides Research TeamEditorial

Updated September 28, 20269 min read

60 WORDS

Short answer

There is no GLP-3 receptor. It does not appear in human receptor nomenclature, it is absent from every pharmacology reference in use, and not one peer-reviewed paper on the molecule uses the term. Yet the retatrutide glp-3 research peptide label has become market shorthand for LY3437943, the investigational Eli Lilly compound that activates three receptors simultaneously: GIP, GLP-1, and glucagon.…

Key takeaways

GLP-3 is not a real receptor; the retatrutide glp-3 research peptide label refers to LY3437943, a triple agonist at the GIP, GLP-1 and glucagon receptors.
Phase 2 obesity data published in the New England Journal of Medicine in 2023 reported 24.2% mean body weight reduction at 48 weeks on the highest dose arm versus 2.1% on placebo.
The weight-loss curve in that phase 2 trial had not plateaued at the 48-week endpoint, which is unusual in obesity pharmacotherapy and shaped the phase 3 TRIUMPH design.
Glucagon receptor agonism raises energy expenditure and hepatic fatty acid oxidation, and it is counterbalanced by the two incretin arms that prevent the glycaemic penalty glucagon would otherwise cause.
Reported retatrutide research side effects in trials were dose-dependent gastrointestinal events during titration plus transient heart rate increases.
A certificate of analysis without mass spectrometry confirms purity but never confirms identity, and lot-specific traceability is the minimum standard for retatrutide research access.

Our team fields more questions about this compound than any other line in metabolic peptide research, and the pattern almost never changes. Researchers arrive knowing one headline weight-loss figure and almost nothing about the glucagon arm, which is precisely the component that makes the molecule pharmacologically novel.

What is the retatrutide GLP-3 research peptide?

The retatrutide glp-3 research peptide is research-grade LY3437943, a single-molecule triple agonist acting at the GIP, GLP-1, and glucagon receptors. GLP-3 is a nickname, not a receptor. Phase 2 obesity data published in the New England Journal of Medicine in 2023 reported mean body weight reduction of 24.2% at 48 weeks on the highest dose studied. The compound remains investigational.

The common oversimplification is that retatrutide is tirzepatide with one extra receptor bolted on. It is not. Adding glucagon receptor agonism changes the energy-balance equation entirely, because glucagon raises energy expenditure and drives hepatic fatty acid oxidation rather than only reducing intake. What follows covers the three-receptor mechanism in plain terms, what the phase 1, phase 2 and ongoing phase 3 literature actually reports including retatrutide research side effects, and how to read a certificate of analysis before any vial reaches a bench.

Why the triple agonist label matters more than the GLP-3 nickname

Retatrutide is a synthetic peptide built around a GIP-analogue backbone, engineered so that one molecule engages three distinct receptor populations at different potencies. Each arm does a different job.

The GLP-1 (glucagon-like peptide-1) receptor arm slows gastric emptying, amplifies glucose-dependent insulin secretion from pancreatic beta cells, and acts on hypothalamic satiety circuits. The GIP (glucose-dependent insulinotropic polypeptide) receptor arm is the second incretin pathway, influencing nutrient handling in adipose tissue and appearing to modulate nausea signalling in the area postrema, which is part of why dual agonists tolerate dose escalation differently from GLP-1 monotherapy.

Then there is the glucagon receptor, and this is where the retatrutide glp-3 research peptide separates from every dual agonist in the literature. Glucagon receptor activation in hepatic tissue increases resting energy expenditure and stimulates fatty acid oxidation in the liver. It also raises hepatic glucose output, which on its own would worsen glycaemic control. The two incretin arms act as the counterweight. That balancing act is the entire engineering problem the molecule was designed to solve, and it is why a glucagon agonist alone never made it as a metabolic candidate.

Reported pharmacokinetics support once-weekly administration in the trial setting, with a half-life measured in days rather than hours. In our experience answering retatrutide research questions, the glucagon arm is the single most under-read part of the file, and it explains most of what makes the published results unusual.

What the published retatrutide research actually reports

The retatrutide scientific research base is small but unusually dense for a compound at this stage. First-in-human work by Coskun and colleagues, published in Cell Metabolism in 2022, characterised LY3437943 as a tri-agonist and established the pharmacokinetic profile used in later studies.

The phase 2 obesity trial led by Jastreboff and colleagues in the New England Journal of Medicine in 2023 is the study everyone cites. Across 48 weeks, participants on the highest dose arm recorded mean body weight reduction of 24.2% against 2.1% on placebo. Trial doses ranged from 1 mg to 12 mg weekly with staged titration, reported here as clinical reference only.

Here is the detail most summaries skip. The weight-reduction curve had not flattened by week 48. In most obesity pharmacotherapy trials the curve bends toward a plateau well before the endpoint, which is what makes the retatrutide trajectory notable and why the phase 3 TRIUMPH programme was designed with longer horizons.

Separate phase 2 work in type 2 diabetes published in The Lancet in 2023 by Rosenstock and colleagues reported HbA1c reductions of roughly two percentage points at higher doses alongside substantial weight change. A phase 2a study in metabolic dysfunction-associated steatotic liver disease published in Nature Medicine in 2024 reported large reductions in hepatic fat content, consistent with the glucagon arm acting directly on liver lipid metabolism.

On retatrutide research side effects, the published pattern is dose-dependent gastrointestinal events, nausea, vomiting, diarrhoea and constipation, concentrated during titration, plus transient increases in heart rate that attenuated over the study period.

Reading documentation before a research compound reaches the bench

A retatrutide research compound is only as trustworthy as the paperwork attached to it, and most retatrutide research documentation circulating online fails on identity rather than purity. Purity and identity are two different tests. A high-performance liquid chromatography (HPLC) trace tells you what fraction of the material is a single species. It does not tell you that the species is retatrutide. Only mass spectrometry, confirming the expected molecular weight, establishes identity.

That gap is the most common failure we see. A certificate showing 99% by HPLC with no mass spec data is a certificate confirming that something is very pure. Batch number, synthesis date, water content and residual solvent data complete the picture, and the certificate should be traceable to the specific lot number printed on the vial rather than to the product line in general.

Lyophilised peptide powder is hygroscopic and photosensitive. Standard laboratory practice is long-term storage of unreconstituted material in a freezer, with reconstituted solution refrigerated and used within a short window, because repeated freeze-thaw cycles and temperature excursions degrade peptide bonds in ways no visual inspection detects. Anyone sourcing retatrutide raw powder research peptide material without lot-specific analysis is running a study on an unknown.

Everything here is research education. These compounds are not FDA-approved drugs, they are supplied for laboratory research use only, and nothing in this article is dosing, administration or protocol guidance for any person. If the question behind your search concerns an animal rather than a bench experiment, talk to your veterinarian, because human trial data does not transfer across species.

Retatrutide GLP-3 Research Peptide: Incretin Compound Comparison

This table sets the triple agonist against the incretin compounds it is most often confused with, so the receptor differences and evidence stage are visible side by side. Regulatory status is the column that matters most for research planning.

Compound	Receptor targets	Published evidence stage	Regulatory status	Professional assessment
Retatrutide (LY3437943)	GIP, GLP-1 and glucagon receptors	Phase 1 and multiple phase 2 trials published; phase 3 TRIUMPH programme ongoing	Investigational; not approved for any indication	The only published triple agonist with human phase 2 data across obesity, type 2 diabetes and liver fat; strictly research-use-only material today
Tirzepatide	GIP and GLP-1 receptors	Completed phase 3 programmes in diabetes and obesity	Approved as a finished drug product under brand names	The closest structural relative; useful as a mechanistic comparator because it isolates what the glucagon arm adds
Semaglutide	GLP-1 receptor only	Extensive phase 3 and cardiovascular outcome data	Approved as a finished drug product under brand names	The single-receptor reference point; the baseline against which dual and triple agonist effect sizes are interpreted
Survodutide	GLP-1 and glucagon receptors	Phase 2 published; phase 3 in progress	Investigational	The dual glucagon comparator; helpful for separating glucagon-driven energy expenditure effects from GIP-driven effects

What If: Retatrutide Research Scenarios

What if the certificate of analysis lists HPLC purity but no mass spectrometry?

Treat the identity of the material as unconfirmed and request lot-specific mass spec data before using it in any experiment. HPLC quantifies how much of the sample is one species; only mass spectrometry matches the observed molecular weight against the expected sequence. Plenty of suppliers publish a clean chromatogram for material that was never sequence-verified, and a truncated or deletion-sequence peptide can run remarkably pure on HPLC alone.

What if the lyophilised powder looks like less material than the vial label states?

Do not judge quantity by the visible cake. Lyophilisation produces wildly variable cake density and volume depending on fill depth, freezing rate and excipient content, so a 10 mg fill can look like a thin film or a full plug. Gravimetric confirmation against the certificate is the only reliable check. A cake that has collapsed into a glassy bead or an oily residue, by contrast, suggests a temperature excursion during shipping and warrants contacting the supplier.

What if my study design needs to isolate the glucagon receptor contribution?

Build in a dual-agonist comparator rather than relying on a placebo arm alone. Because retatrutide activates three receptors at once, a placebo-controlled design tells you the combined effect and nothing about attribution. Running a GIP and GLP-1 dual comparator alongside the triple agonist is what allows the glucagon-driven energy expenditure and hepatic lipid effects to be separated from incretin-driven appetite and insulin effects.

What if I can only find secondary summaries rather than primary papers?

Go to PubMed and search the development code LY3437943 rather than the trade nickname. Retatrutide research resources indexed under the compound code capture the phase 1 pharmacokinetic work, the phase 2 obesity and type 2 diabetes trials, and the hepatic steatosis sub-studies that summary articles routinely miss. The clinical trial registry entries for the TRIUMPH programme also list endpoints and enrolment criteria that no secondary source reproduces accurately.

The Uncomfortable Truth About Retatrutide Outside a Clinical Trial

Let us be direct about this: every impressive number in the retatrutide glp-3 research peptide literature was generated using material manufactured to pharmaceutical standards, characterised at every batch, and administered under trial protocol. None of those conditions apply to grey-market supply. A compound sold with a generic certificate, no lot traceability and no mass spectrometry is not the molecule in the NEJM paper; it is an unknown with a familiar name. The phase 3 programme is still running, the long-term safety file is incomplete, and pretending otherwise does not change the regulatory status.

Researchers working across adjacent metabolic pathways can review our metabolic peptides collection and oral research compounds, check lot documentation on our certificates of analysis page, or browse the full research catalog. Compounds frequently studied alongside incretin pathway work include AOD-9604, 5-Amino-1MQ and MOTS-c, each supplied with batch-level analysis.

The retatrutide glp-3 research peptide is a case study in how quickly a marketing label can outrun the science it describes. A nickname invented to make a triple agonist sound like the next number in a sequence has done real damage to how the compound is understood, because it frames glucagon receptor agonism as an incremental upgrade rather than the mechanistic departure it actually is. Read the receptor pharmacology before you read the weight-loss headline. The interesting part of this molecule was never how much weight came off in 48 weeks. It was which liver enzyme pathways were burning to make that happen.

References

Peer-reviewed sources on Retatrutide indexed in PubMed, listed for research context. Real Peptides supplies Retatrutide for laboratory research use only.

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proceedings (Baylor University. Medical Center), 2025. PMID 40291085. doi:10.1080/08998280.2025.2456441
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. Journal of basic and clinical physiology and pharmacology, 2025. PMID 40728138. doi:10.1515/jbcpp-2025-0113
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European journal of clinical pharmacology, 2024. PMID 38367045. doi:10.1007/s00228-024-03646-0
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism open, 2024. PMID 39318607. doi:10.1016/j.metop.2024.100321
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, obesity & metabolism, 2026. PMID 41090431. doi:10.1111/dom.70209
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026. PMID 42250575. doi:10.1016/S0140-6736(26)00967-0
Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules, 2025. PMID 40563436. doi:10.3390/biom15060796
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025. PMID 40609566. doi:10.1016/S2213-8587(25)00092-0

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

It means nothing in receptor biology. There is no GLP-3 receptor in human pharmacology, and no peer-reviewed paper on retatrutide uses the term. GLP-3 is market shorthand that emerged because retatrutide follows GLP-1 agonists and GIP/GLP-1 dual agonists in sequence, but the compound actually targets three receptors: GIP, GLP-1 and glucagon.

Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide activates those two plus the glucagon receptor. The glucagon arm is the functional difference, because glucagon receptor agonism increases resting energy expenditure and hepatic fatty acid oxidation rather than only reducing food intake. That third arm also raises hepatic glucose output, which the two incretin arms offset.

The phase 2 trial published in the New England Journal of Medicine in 2023 reported mean body weight reduction of 24.2% at 48 weeks in the highest dose arm, compared with 2.1% on placebo. Notably, the weight-reduction curve had not reached a plateau at the 48-week endpoint. These are clinical trial findings reported for reference, not guidance for any individual.

The published phase 2 data describe dose-dependent gastrointestinal adverse events as the dominant pattern, including nausea, vomiting, diarrhoea and constipation, concentrated during the dose-escalation period. Transient increases in heart rate were also reported and attenuated over the course of the studies. Longer-term safety data is still being generated through the ongoing phase 3 TRIUMPH programme.

No. Retatrutide is an investigational compound with no FDA approval for any indication. Its phase 3 programme is ongoing, which means no finished drug product exists and no approved labelling has been issued. Research-grade material is supplied strictly for laboratory research use and is not intended for human or veterinary consumption.

Standard laboratory practice for lyophilised peptides is freezer storage of unreconstituted powder, protected from light and moisture, with reconstituted solution kept refrigerated and used within a short defined window. Peptides are hygroscopic and degrade with repeated freeze-thaw cycles. Degradation from a temperature excursion is not visible to the eye, which is why handling records matter as much as the storage temperature itself.

At minimum it should show HPLC purity, mass spectrometry confirming the expected molecular weight, the specific lot number matching the vial, the synthesis or test date, and water or residual solvent content. HPLC alone establishes purity but never identity. A certificate that cannot be traced to the exact lot in your hand is documentation for a product line, not for your material.

Research-grade material is sold through peptide suppliers as lyophilised powder in milligram vials, with pricing varying widely by supplier, vial size, purity level and the depth of analytical documentation provided. Cost per milligram is rarely the useful comparison. The meaningful variable is whether lot-specific third-party analysis is included, because unverified material at any price produces uninterpretable data.

Retatrutide raw powder research peptide listings do circulate, but bulk unvialed powder is the highest-risk format because it typically arrives without lot-level analysis and without controlled fill weights. Weighing out sub-milligram quantities of a hygroscopic peptide outside a controlled environment introduces both moisture uptake and gravimetric error. Vialed, lot-documented material is the defensible option for any study intended to produce reproducible results.

Modest heart rate increases are a documented class effect across incretin-based compounds and were reported in the retatrutide phase 2 studies as transient, attenuating over the study period. The glucagon receptor arm may contribute, since glucagon has recognised cardiovascular effects alongside its metabolic ones. The precise contribution of each receptor arm has not been separated in published human data.

Search PubMed using the development code LY3437943 rather than the trade nickname, which surfaces the phase 1 pharmacokinetic characterisation, the phase 2 obesity and type 2 diabetes trials, and the hepatic steatosis sub-study. Clinical trial registry entries for the TRIUMPH phase 3 programme list endpoints, enrolment criteria and study durations that secondary summaries routinely misreport.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA